Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2006 3
2007 2
2008 5
2009 3
2010 1
2011 2
2012 2
2013 2
2014 2
2015 1
2016 2
2017 1
2021 1
2022 2
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Childress AC, Marraffino A, Cutler AJ, Oh C, Brams MN. Childress AC, et al. J Child Adolesc Psychopharmacol. 2023 Mar;33(2):51-58. doi: 10.1089/cap.2022.0076. Epub 2023 Feb 20. J Child Adolesc Psychopharmacol. 2023. PMID: 36809150 Free PMC article. Clinical Trial.
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged 6 years with attention-deficit/hyperactivity disorder (ADHD). ...
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged 6 years with attention …
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D. Lower EE, et al. J Pain Symptom Manage. 2009 Nov;38(5):650-62. doi: 10.1016/j.jpainsymman.2009.03.011. J Pain Symptom Manage. 2009. PMID: 19896571 Free article. Clinical Trial.
Cancer and its treatment can induce subjective and objective evidence of diminished functional capacity encompassing physical fatigue and cognitive impairment. Dexmethylphenidate (D-MPH; the D-isomer of methylphenidate) was evaluated for treatment of chemotherapy-related f …
Cancer and its treatment can induce subjective and objective evidence of diminished functional capacity encompassing physical fatigue and co …
The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder.
Reimherr FW, Gift TE, Steans TA, Reimherr ML, Rosenberg LI, Wilson M, Marchant BK. Reimherr FW, et al. J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):445-453. doi: 10.1097/JCP.0000000000001592. Epub 2022 Aug 18. J Clin Psychopharmacol. 2022. PMID: 35977005 Clinical Trial.
METHODS: Initially, 559 stimulant-naive and 174 prior stimulant nonresponders received methylphenidate osmotic-release oral system, dexmethylphenidate hydrochloride, lisdexamfetamine, or mixed amphetamine salts. After 5 weeks, 168 stimulant-naive patients and 68 pri …
METHODS: Initially, 559 stimulant-naive and 174 prior stimulant nonresponders received methylphenidate osmotic-release oral system, dexme …
Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.
Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH. Stein MA, et al. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581-8. doi: 10.1089/cap.2011.0018. Epub 2011 Dec 2. J Child Adolesc Psychopharmacol. 2011. PMID: 22136094 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the dose effects of long-acting extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts (ER MAS) on attention-deficit/hyperactivity disorder (ADHD) symptom dimensions, global and specific impairments, and common adverse events as …
OBJECTIVE: To compare the dose effects of long-acting extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts ( …
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.
Childress AC, Cutler AJ, Patel M, Oh C. Childress AC, et al. J Child Adolesc Psychopharmacol. 2023 May;33(4):134-142. doi: 10.1089/cap.2023.0012. J Child Adolesc Psychopharmacol. 2023. PMID: 37204277 Free PMC article. Clinical Trial.
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged 6 years with attention-deficit/hyperactivity disorder (ADHD). ...
Objective: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged 6 years with attention …
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. Wigal S, et al. J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14. doi: 10.1097/01.chi.0000138351.98604.92. J Am Acad Child Adolesc Psychiatry. 2004. PMID: 15502600 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of dexmethylphenidate hydrochloride (d-MPH, Focalin) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and to test an a priori hypothesis that d-MPH would have a longer duration of action than d,l-thr …
OBJECTIVE: To evaluate the efficacy and safety of dexmethylphenidate hydrochloride (d-MPH, Focalin) for the treatment of atten …
Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A. Silva R, et al. Psychopharmacol Bull. 2008;41(1):19-33. Psychopharmacol Bull. 2008. PMID: 18362868 Clinical Trial.
The purpose of this study was to compare the efficacy and safety of extended-release dexmethylphenidate (d-MPH-ER) to that of d,l-MPH-ER and placebo in children with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting. ...
The purpose of this study was to compare the efficacy and safety of extended-release dexmethylphenidate (d-MPH-ER) to that of d,l-MPH …
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
Lyon GJ, Samar SM, Conelea C, Trujillo MR, Lipinski CM, Bauer CC, Brandt BC, Kemp JJ, Lawrence ZE, Howard J, Castellanos FX, Woods D, Coffey BJ. Lyon GJ, et al. J Child Adolesc Psychopharmacol. 2010 Aug;20(4):283-9. doi: 10.1089/cap.2010.0032. J Child Adolesc Psychopharmacol. 2010. PMID: 20807066 Free PMC article. Clinical Trial.
OBJECTIVE: The aim of this study was to conduct a pilot study testing whether single-dose, immediate-release dexmethylphenidate (dMPH) can facilitate tic suppression in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and Tourette's disorder (T …
OBJECTIVE: The aim of this study was to conduct a pilot study testing whether single-dose, immediate-release dexmethylphenidate (dMPH …
Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.
Patrick KS, Straughn AB. Patrick KS, et al. Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. Epub 2016 Jan 4. Drug Metab Dispos. 2016. PMID: 26729760 Free PMC article. Clinical Trial.
The postulate that twice the milligram/kilogram dose of dl-methylphenidate (dl-MPH) would result in equal exposure to d-MPH compared with half that milligram/kilogram dose of the chiral switch product dexmethylphenidate (d-MPH) was tested. Using a randomized, crossover stu …
The postulate that twice the milligram/kilogram dose of dl-methylphenidate (dl-MPH) would result in equal exposure to d-MPH compared with ha …
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder.
Fainberg G, Leitner Y, Zur D, Klein A, Mezad-Koursh D. Fainberg G, et al. J Child Adolesc Psychopharmacol. 2022 Dec;32(10):533-538. doi: 10.1089/cap.2022.0074. J Child Adolesc Psychopharmacol. 2022. PMID: 36548361 Clinical Trial.
Objective: To evaluate the short-term effect of dexmethylphenidate (D-MPH) on visual acuity (VA), pupil size, anterior chamber depth, and accommodation-convergence reflex in children treated with D-MPH for attention-deficit/hyperactivity disorder (ADHD). ...
Objective: To evaluate the short-term effect of dexmethylphenidate (D-MPH) on visual acuity (VA), pupil size, anterior chamber depth, …
33 results